Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Linagliptin is a xanthine-based dipeptidyl peptidase (DPP)-4 inhibitor that is now available in numerous countries worldwide for the treatment of type 2 diabetes mellitus (T2DM). The aim of this study was to evaluate further the mechanisms underlying the improvements in glycemic control observed with linagliptin. The effects of linagliptin on DPP-4, pharmacodynamic parameters, and glycemic control versus placebo were assessed in patients with inadequately controlled T2DM.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Diabetes Therapy |
Vol/bind | 3 |
Udgave nummer | 1 |
Sider (fra-til) | 10 |
ISSN | 1869-6953 |
DOI | |
Status | Udgivet - nov. 2012 |
ID: 45841462